Skip to main content
SpringerLink
Log in

Anxiolytika und Sedativa/Hypnotika

  • Chapter
  • First Online:
Neuro-/Psychopharmaka im Kindes- und Jugendalter

  • 6053 Accesses

Zusammenfassung

Unter der Wirkstoffklasse Anxiolytika und Sedativa/Hypnotika wird eine sehr heterogene Gruppe von Neuro-/Psychopharmaka zusammengefasst. Trotz unterschiedlicher Wirkmechanismen haben sie ein gemeinsames klinisches Wirkungsspektrum und werden zur symptomatischen Behandlung von Angsterkrankungen und Schlafstörungen eingesetzt. Diese Stoffklasse ist aufgrund des dosisabhängigen kontinuierlichen Wirkungsspektrums von Anxiolyse über Sedierung und Schlaf bis Narkose nicht klar voneinander abgrenzbar. In diesem Kapitel wird der Wissensstand der in der Kinder- und Jugendpsychiatrie verwendeten Anxiolytika und Sedativa/Hypnotika hinsichtlich Wirkmechanismen, zugelassenen Indikationen, Studienlage zur Wirksamkeit und Sicherheit, Dosierungen, unerwünschten Arzneimittelwirkungen, Pharmakawechselwirkungen, Kontraindikationen und besonderen Vorsichtsmaßnahmen zusammengefasst. Mithilfe dieses Wissens sollen klinisch tätige Ärzte diese Neuro-/Psychopharmaka individuell, wirksam und sicher anwenden können.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

Weiterführende Literatur

  • Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME (2014) Clinical practice guideline: The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztbl Int 111:473–480

    Google Scholar 

  • Möhler H (2011) The rise of a new GABA pharmacology. Neuropharmacology 60:1042–1049

    Article  PubMed  Google Scholar 

  • Schatzberg AF, Nemeroff CB (Hrsg) (2009) Textbook of psychopharmacology, 4. Aufl. American Psychiatric Publishing, Washington

    Google Scholar 

  • Stieler-Melfsen S, Walitza S (Hrsg) (2013) Soziale Angst und Schulangst. Entwicklungsrisiken erkennen und behandeln. Beltz, Weinheim

    Google Scholar 

Zitierte Literatur

  • AACAP Official Action (2007) Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Psy 46:267–283

    Article  Google Scholar 

  • Baldwin DS, Anderson IM, Nutt DJ et al (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28:403–439

    Article  PubMed  Google Scholar 

  • Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – First revision. World J Biol Psychia 9:248–312 (WFSBP Task Force on Treatment Guidelines for Anxiety Obsessive-Compulsive Post-Traumatic Stress Disorders)

    Article  Google Scholar 

  • Bezchlibnyk-Butler KZ, Virani AS (Hrsg) (2007) Clinical handbook of psychotropic drugs for children and adolescents, 2. Aufl. Hogrefe & Huber, Cambridge

    Google Scholar 

  • Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S (2007) SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Psy 46:1622–1632

    Article  Google Scholar 

  • Berney T, Kolvin I, Bhate SR, Garside RF, Jeans J, Kay B, Scarth L (1981) School phobia: a therapeutic trial with clomipramine and short-term outcome. Brit J Psychiat 138:110–118

    Article  CAS  PubMed  Google Scholar 

  • Bernstein GA, Garfinkel BD, Borchardt CM (1990) Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Psy 29:773–781

    Article  CAS  Google Scholar 

  • Bernstein GA, Borchardt CM, Perwien AR, Crosby RD, Kushner MG, Thuras PD, Last CG (2000) Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Psy 39:276–283

    Article  CAS  Google Scholar 

  • Birmaher B, Axelson DA, Monk K et al (2003) Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Psy 42:415–423

    Article  Google Scholar 

  • Buscemi N, Vandermeer B, Friesen C et al (2007) The efficacy and safety of drug treatment for chronic insomnia in adults: a mety-analyis of RCTs. J Gen Intern Med 22:1335–1350

    Article  PubMed  PubMed Central  Google Scholar 

  • Da Costa CZG, de Morais RMCB, Zanetta DMT et al (2013) Comparison among clomiparamine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. J Child Adol Psychopharmacol 23:687–692

    Article  Google Scholar 

  • Dilling H, Mombour W, Schmidt MH (Hrsg) (2013) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien, 9. Aufl. Huber, Bern

    Google Scholar 

  • Domschke K (2013) Angsterkrankungen: Genetische Grundlagen. Neuroforum 3:118–125

    Google Scholar 

  • Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249–253

    Article  CAS  PubMed  Google Scholar 

  • Falkai P, Wittchen H-U (Hrsg) (2015) American Psychiatric Association. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. Hogrefe, Göttingen

    Google Scholar 

  • Feinstein JS, Buzza C, Hurlemann R et al (2013) Fear und panic in humans with bilateral amygdala damage. Nat Neurosci 16:270–272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gao K, Muzina D, Gajwani P, Calabrese JR (2006) Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiat 67:1327–1340

    Article  CAS  Google Scholar 

  • Granville-Grossman KL, Turner P (1966) The effect of propranolol on anxiety. Lancet 1:788–790

    Article  CAS  PubMed  Google Scholar 

  • Hiemke C, Baumann P, Bergemann N et al (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry – Update 2011. Pharmacopsychiatry 44:195–235 (The TDM group of the AGNP)

    Article  Google Scholar 

  • Hidalgo RB, Tupler LA, Davidson JR (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864–872

    Article  CAS  PubMed  Google Scholar 

  • Ipser JC, Stein DJ, Hawkrige S, Hoppe L (2009) Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database System Rev CD005170

    Google Scholar 

  • Kasper S, Gastpar M, Müller WE, Volz H-P, Möller H-J, Schläfke S, Dienel A (2014) Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blin comparison to placebo and paroxetine. Int J Neuropsychopharmacol 17:859–869

    Article  CAS  PubMed  Google Scholar 

  • Klein RG, Koplewicz HS, Kanner A (1992) Imipramine treatment of children with separation anxitey disorder. J Am Acad Child Psy 31:21–28

    Article  CAS  Google Scholar 

  • March JS, Entusah AR, Rynn M, Albano AM, Tourian KA (2007) A randomized controlled trial of venlafaxine ER versus pedriatric social anxiety disorder. Biol Psychiat 62:1149–1154

    Article  CAS  PubMed  Google Scholar 

  • Möhler H (2012) The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 67:42–53

    Article  Google Scholar 

  • Möller HJ, Volz HP, Reimann IR, Stoll KD (2001) Opipramol for the treatment of generalized anxiety. A placebo controlled trial including an alprazolam treated group. J Clin Psychopharmacol 21:59–65

    Article  PubMed  Google Scholar 

  • Morin CM, Koettler U, Bastien C, Ware JC, Wooten V (2005) Valerian-hops combination and diphenhydramine for treating insomnia: A randomized placebo-controlled clinical trial. Sleep 28:1465–1471

    PubMed  Google Scholar 

  • Müller WE, Hartmann H (1995) Definition, Einteilung, Chemie. In: Riederer P, Laux G, Pöldinger W (Hrsg) Tranquilizer und Hypnotika. Neuro-Psychopharmaka. Ein Therapie-Handbuch, Bd. 2. Springer, Wien, S 1–12

    Google Scholar 

  • Neubauer (2007) The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med 3(Suppl):S11–S15

    PubMed  PubMed Central  Google Scholar 

  • Pape H-C (2013) Furcht, Angst, Angsterkrankungen. Neuroforum 3:90–91

    Google Scholar 

  • Rynn MA, Riddle MA, Young PP, Kunz MR (2007) Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiat 164:290–300

    Article  PubMed  Google Scholar 

  • Sachser N, Lesch K-P (2013) Das Zusammenspiel von Genotyp und Umwelt bei der Entwicklung von Furcht und Angst. Neuroforum 3:104–110

    Google Scholar 

  • Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A (2011) Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharm 21:841–860

    Article  CAS  Google Scholar 

  • Schuckit MA, Hesselbrock V (1994) Alcohol dependence and anxiety disorders: what is the relationship? Am J Psychiat 151:1723–1734

    Article  CAS  PubMed  Google Scholar 

  • Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008) Clinical guideline for the evaluation of chronic insomnia in adults. J Clin Sleep Med 4:487–504

    PubMed  PubMed Central  Google Scholar 

  • Stieler-Melfsen S, Walitza S (Hrsg) (2013) Soziale Angst und Schulangst. Entwicklungsrisiken erkennen und behandeln. Weinheim, Basel

    Google Scholar 

  • Strawn JR, Sakolsky DJ, Rynn MA (2012a) Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adol Psych Cl 21:527–539

    Article  Google Scholar 

  • Strawn JF, Wehry AM, DelBello MP, Rynn MA, Strakowski S (2012b) Establishing the neurobiologic basic of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety 29:328–339

    Article  PubMed  Google Scholar 

  • The Research Unit on Pediatric Psychopharmacology Anxiety Study Group (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolecents. New Engl J Med 344:1279–1285

    Article  Google Scholar 

  • Wagner KD, Berard R, Stein MB et al (2004) A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiat 61:1153–1162

    Article  CAS  PubMed  Google Scholar 

  • Walkup JT, Albano AM, Piacentini J et al (2008) Cognitive behavioral therapy. Sertraline, or a combination in childhood anxiety. New Engl J Med 359:2753–2766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wotjak CT, Pape H-C (2013) Neuronale Schaltkreise von Furchtgedächtnis und Furchtextinktion. Neuroforum 3:92–102

    Google Scholar 

  • Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000) Trends in prescribing of psychotropic medications to preschoolers. JAMA 283:1025–1030

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Kinder- u. Jugendpsychiatrie, Psychosomatik u. Psychotherapie, Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Füchsleinstraße 15, 97080, Würzburg, Deutschland

    Dr. med. Su-Yin Dang, Prof. Dr. rer. nat. Manfred Gerlach & Prof. Dr. med. Andreas Warnke

  2. Klinik für Psychiatrie und Psychotherapie im Kindes- und Jugendalter, Universitätsklinikum Tübingen, Osianderstraße 14-16, 72076, Tübingen, Deutschland

    Prof. Dr. med. Tobias Renner

Authors
  1. Dr. med. Su-Yin Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. rer. nat. Manfred Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Tobias Renner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. Andreas Warnke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Gerlach .

Editor information

Editors and Affiliations

  1. Zentrum für Seelische Gesundheit, Universitätsklinikum Würzburg, Würzburg, Germany

    Manfred Gerlach

  2. Privatklinik für Seelische Gesundheit, J, HEMERA Klinik, Bad Kissingen, Germany

    Claudia Mehler-Wex

  3. Zentrum für Kinder- und Jugendpsychiatri, Universität Zürich, Zürich, Zürich, Switzerland

    Susanne Walitza

  4. Zentrum für Seelische Gesundheit, Universitätsklinikum Würzburg, Würzburg, Bayern, Germany

    Andreas Warnke

  5. Abteilung Kinder Jugendpsychiatrie, Kliniken der Stadt Köln gGmbH, Köln, Germany

    Christoph Wewetzer

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dang, SY., Gerlach, M., Renner, T., Warnke, A. (2016). Anxiolytika und Sedativa/Hypnotika. In: Gerlach, M., Mehler-Wex, C., Walitza, S., Warnke, A., Wewetzer, C. (eds) Neuro-/Psychopharmaka im Kindes- und Jugendalter. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48624-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48624-5_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48623-8

  • Online ISBN: 978-3-662-48624-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation